-
Article
Open AccessA non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer
miR-346 was identified as an activator of Androgen Receptor (AR) signalling that associates with DNA damage response (DDR)-linked transcripts in prostate cancer (PC). We sought to delineate the impact of miR-3...
-
Article
Open AccessAndrogen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents
Abiraterone and enzalutamide are novel endocrine treatments that abrogate androgen receptor (AR) signalling in castration-resistant prostate cancer (CRPC). Here, we developed a circulating tumour cells (CTCs)-...
-
Article
Open AccessValidation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail
Predictive biomarker development is a key challenge for novel cancer therapeutics. We explored the feasibility of next-generation sequencing (NGS) to validate exploratory genomic biomarkers that impact phase I...
-
Article
Open AccessFirst-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
Prostate cancer remains dependent of androgen receptor (AR) signalling, even after emergence of castration resistance. EZN-4176 is a third-generation antisense oligonucleotide that binds to the hinge region (e...
-
Article
Multiple- and single-objective approaches to laminate optimization with genetic algorithms
In this paper an application of a genetic algorithm to a material- and sizing-optimization problem of a plate is described. This approach has obvious advantages: it does not require any derivative information ...
